Hesperos Inc. Established in 2015 by Drs. Shuler and Hickman, the company aims to accelerate drug discovery through their groundbreaking Human-on-a-Chip® technology.

With a team of biologists, surface chemists, and engineers, Hesperos develops some of the world's most advanced organs-on-a-chip platforms. Their custom models can replicate up to 5-organ or tissue types, recreating key components of organs in a fully interconnected, functional system. Using chemically patterned microchips, Hesperos enables real-time, non-invasive monitoring of organ activity, detecting even the slightest changes over time.

These models provide pre-clinical insight into the efficacy and off-target toxicity of both single and multi-drug treatments. Hesperos' mission is to accelerate drug development and provide safety and efficacy data for the pharmaceutical, cosmetic, and food industries. They envision a world where every disease has a treatment, every patient has hope, and animals are no longer used for chemical testing or drug discovery.

With their Human-on-a-Chip platform, Hesperos offers compound safety and efficacy testing services using advanced, multi-organ microphysiological systems. Their platform allows evaluation of drug compounds, including parent compounds and their metabolites, and enables PK/PD extrapolation to in vivo outcomes. The flexible platform can be tailored to reproduce specific disease states, evaluate drug delivery methods, and investigate the effects of compounds or combinations.

Hesperos' Human-on-a-Chip platform has been successfully used by pharmaceutical, cosmetic, and government entities to better understand specific disease states and the human response to therapeutics. Their efficacy data from a microphysiological system even led to the authorization of a clinical trial, a significant milestone in validating the technology. Led by a team of experienced professionals, including Dr.

James J. Hickman as Chief Scientist, Dr. James Kronauge as Chief Executive Officer, and Dr.

Michael L. Shuler as Co-Founder and President, Hesperos continues to push the boundaries of organ-on-a-chip technology. Their story began in the early 1990s when Dr.

Shuler observed the limitations of animal models and envisioned a more predictive model. Collaborating with Dr. Hickman, they developed multi-organ systems with functional readouts, revolutionizing the field.

Since then, Hesperos has made significant progress and continues to provide innovative solutions for drug and cosmetic researchers